A Double-Blind, Placebo-Controlled, Cross-Over Study of Ranolazine in Patients With Coronary Artery Disease for the Treatment of Painful Polyneuropathy.

Trial Profile

A Double-Blind, Placebo-Controlled, Cross-Over Study of Ranolazine in Patients With Coronary Artery Disease for the Treatment of Painful Polyneuropathy.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2014

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Polyneuropathy
  • Focus Therapeutic Use
  • Sponsors CV Therapeutics; Gilead Sciences
  • Most Recent Events

    • 09 Dec 2009 CV Therapeutics company acqiured by Gilead Sciences hence replaced in assocation field as sponsor and affiliate as reported by ClinicalTrials.gov.
    • 16 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top